Soligenix Receives EMA Positive Opinion for Dusquetide in Behçet's Disease Treatment

The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion for Soligenix Inc.'s dusquetide in the treatment of Behçet's disease, marking a significant regulatory milestone for the rare inflammatory disease therapeutic. This positive opinion represents a crucial step toward formal orphan drug designation by the European Commission, which would provide development incentives including protocol assistance, reduced regulatory fees, and up to ten years of market exclusivity following approval. The designation specifically applies to the SGX945 program, which focuses on dusquetide as an innate defense regulator designed to modulate rather than suppress the body's immune response.

Soligenix CEO and president Christopher J. Schaber emphasized the importance of this development, stating that Behçet's disease represents an area of significant unmet medical need where current treatment options remain limited. The company's focus on rare diseases and areas of unmet medical need aligns with the orphan drug designation process, which aims to encourage development of treatments for conditions affecting small patient populations. Dusquetide's classification as an innate defense regulator represents a novel approach to inflammatory disease treatment, potentially offering advantages over traditional immunosuppressive therapies that carry significant side effect risks.

The positive opinion from the EMA's Committee for Orphan Medicinal Products validates the scientific rationale behind dusquetide's development and could accelerate the program's progress through regulatory pathways. For patients with Behçet's disease, this milestone represents potential progress toward new treatment options for a condition characterized by recurrent oral and genital ulcers, skin lesions, and potentially serious complications affecting multiple organ systems. The regulatory milestone comes as Soligenix continues to advance its pipeline of treatments for rare diseases, with dusquetide representing one of several therapeutic candidates under development by the biopharmaceutical company.

Investors and stakeholders can access additional information about Soligenix through the company's newsroom at https://ibn.fm/SNGX, which provides updates on the company's progress across its development portfolio. The orphan drug designation process in Europe follows similar pathways to those established in other regulatory jurisdictions, with the goal of facilitating development of treatments for rare conditions that might otherwise receive limited research attention due to small market sizes. The positive opinion from the EMA committee represents a vote of confidence in dusquetide's potential to address the significant challenges faced by Behçet's disease patients, who currently have limited therapeutic options available.